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Abstract
Modern treatments for Type 1 diabetes (T1D) use devices known as artificial
pancreata (APs), which combine an insulin pump with a continuous glucose
monitor (CGM) operating in a closed-loop manner to control blood glucose levels.
In practice, poor performance of APs (frequent hyper- or hypoglycemic events) is
common enough at a population level that many T1D patients modify the algorithms
on existing AP systems with unregulated open-source software. Anecdotally, the
patients in this group have shown superior outcomes compared with standard of
care, yet we do not understand how safe any AP system is since adverse outcomes
are rare. In this paper, we construct generative models of individual patients’
physiological characteristics and eating behaviors. We then couple these models
with a T1D simulator approved for pre-clinical trials by the FDA. Given the
ability to simulate patient outcomes in-silico, we utilize techniques from rare-event
simulation theory in order to efficiently quantify the performance of a device with
respect to a particular patient. We show a 72,000× speedup in simulation speed
over real-time and up to 2-10 times increase in the frequency which we are able to
sample adverse conditions relative to standard Monte Carlo sampling. In practice
our toolchain enables estimates of the likelihood of hypoglycemic events with
approximately an order of magnitude fewer simulations.
1 Introduction
T1D impacts more than 1,000,000 people in the US [11]. Patients are often diagnosed with T1D as
children, and for the rest of their lives they are responsible for calculating and administering doses of
insulin, a potent, lethal drug [14]. The consequences of poor T1D management are severe. Patients
who receive too little insulin experience hyperglycemia, a condition which leads to permanent organ
damage. On the other hand, excessive doses of insulin cause hypoglycemia, a potentially fatal
condition [12]. Modern treatment systems automatically monitor blood glucose levels and deliver
insulin to T1D patients [14]. Commonly known as artificial pancreata (APs), these devices combine
an insulin pump with a continuous glucose monitor (CGM) operating in a closed-loop manner to
control blood glucose levels.
Fundamentally, the system defined by a T1D patient controlled with an AP is underactuated. Specifi-
cally, APs can only control insulin delivery, which lowers blood glucose levels; APs do not currently
have any way to increase blood glucose levels. Typical methods to increase blood glucose levels,
like eating food, are unavailable when the patient is sleeping or otherwise incapacitated. As such,
AP algorithms are conservative in order to prevent hypoglycemic episodes for which the system has
no direct actuation authority to escape. In practice, poor performance (e.g. hyper- or hypoglycemic
events occurring too frequently) is common enough at a population level that more than 1,000
patients with T1D have modified the algorithms on existing AP systems with unregulated open-source
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software [9]. The patients in this group have anecdotally shown superior outcomes compared with
standard of care, and yet we do not accurately know how safe the systems truly are.
In this work, we aim to uncover the probability of failure for an AP under a data-driven distribution
of T1D patient behavior and physiology. Specifically, we consider the scenario of overnight fasting, a
dangerous time for T1D patients. Using an FDA-approved simulator for T1D patients’ physiology, we
investigate the last evening meal and overnight fasting period. Our data-driven distribution consists
of the carbohydrate composition of the evening meal, the fasting duration, and internal physiological
parameters for a T1D patient. We use adaptive importance sampling to iteratively learn an estimator
that efficiently learns the (rare) probability of a hypoglycemic event. Compared to naive Monte
Carlo sampling, our adaptive importance sampling method increases the frequency of sampling rare
hypoglycemic events and more accurately estimates the probability of these events. Indeed, for the
same number of samples, we find 2-10× as many hypoglycemic events and our estimates of the
probability of these events have 2-4× smaller variance.
2 Simulator & Population Modeling
Simulator We use an implementation of the 2008 UVa Padova simulator [4] for simulating T1D
patients. This simulator is composed of a system of ordinary differential equations modeling the
internal dynamics of of a patient. The system is composed primarily of three subsystems: glucose
physiology, insulin physiology, and carbohydrate ingestion physiology. The simulator has been
approved for preclinical trials by the FDA [2].
Eating and Overnight Fasting Behavior Because we are concerned with the overnight behavior
of an AP, we build a distribution of evening meals and overnight fasting times of T1D patients.
Unfortunately, there are few publicly available surveys of T1D behavior. Therefore, we estimate a
sample using the National Health and Nutrition Examination Survey (NHANES), a representative
cross-sectional survey of the US population [5]. Nevertheless, even NHANES does not explicitly
classify whether patients have type 1 or type 2 diabetes. As outlined by Menke et al. [10], we define
T1D individuals in NHANES as those who started insulin within 1 year of diabetes diagnosis, are
currently using insulin and were diagnosed with diabetes under age 40. NHANES collects two
consecutive days’ worth of eating behavior for survey participants, including mealtimes as well as
nutritional and caloric information of each meal. We define meals as ingestion of food that contains
at least 1 calorie, and we define overnight fasting as the longest period of fasting greater than 5 hours
that starts after 4pm on the first day and ends before 1pm on the second day. We fit a logit-normal
distribution to these two variables since it has the ability to approximate the shape of beta and normal
distributions while also having compact support. The latter fact is important since we want to prevent
unrealistic tail behavior. The details of the model are in Appendix A.1.
Physiological Parameters Thirty sample T1D patients (subpopulations of 10 children, 10 ado-
lescents, 10 adults) are available for use with the UVa Padova simulator [4]. The rarity of data for
T1D necessitates a more personalized approach to analyzing risk and certifying safety of artificial
pancreata. As such, we build generative models for physiological parameters focusing on small
variations in the 61 parameters per patient, since we know that each of the thirty realizations of
parameters is in fact realistic. We design logit-normal distributions around each patient’s parameters
by first setting the compact interval range as 1/10 the interval range for the entire subpopulation
centered at the patient’s parameters. The details can be found in Appendix A.2. This covariance
structure we derive encodes the fact that we have no knowledge of the covariance of the small
variations in the 61 parameters for an individual patient.
3 Rare-event simulation
Personalized clinical evaluation of an AP for a particular patient profile—especially one modified
from its original settings—is infeasible due to the high costs and inherent dangers posed to trial
subjects. Formal verification methods are challenging to apply due to the difficultly in specifying the
operating domain. For example, a patient may have run a marathon the previous day, dramatically
increasing her insulin sensitivity.
Instead of introducing completely ad-hoc restrictions to the set of scenarios under consideration, we
consider a data-driven a probabilistic approach. We posit a base distribution X ∼ P0 on the set of
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initial conditions X , and denote by f : X → R a continuous measure of risk; a natural measure for
an artificial pancreas is given by the minimum blood glucose level over a period of interest. Then,
our goal is to evaluate the probability of an adverse event
pγ := P0(f(X) ≤ γ),
based on samplesX1, X2, . . . and rollouts f(X1), f(X2), . . . from our simulator. Here, the parameter
γ > 0 is a threshold that defines an “adverse event”; if f(x) denotes the minimum glucose level over
a rollout, then γ = 70 is the threshold for a clinical definition of a hypoglycemic event [3].
Our probabilistic approach rests on the notion of a base distribution P0, which could introduce
subjective valuations of what constitutes a realistic scenario. To alleviate these issues in a system-
atic manner, we use data-driven model whenever population level distributions are deemed to be
meaningful at the individual level as well (e.g. amount of carbohydrates consumed per meal). To
model variations in personalized measurements, we account for sensor noise and uncertainty in
physiological parameters by postulating a logit-normal distribution with small amounts of variance.
We combine: (1) data-driven estimation approach for core exogenous sources of uncertainties, e.g.
meals and fasting (2) autoregressive moving average process noise for sensor measurements (3) white
noise to estimates of unobservable physiological parameters. Through this effort we are able to
represent three different sources of randomness in our base distribution P0.
For reliable control algorithms, an adverse event will be rare, and the probability pγ close to 0. We
treat this as a rare event simulation problem (see [1, Chapter VI] for an overview of this topic), and use
adaptive importance sampling techniques to accelerate our evaluation. To address the shortcomings
of the naive Monte Carlo method for estimating rare event probabilities pγ , we use an adaptive impor-
tance sampling approach [1]. Our goal is to find an importance sampling distribution that produces
estimates with low variance. The optimal importance-sampling distribution for estimating pγ is given
by the conditional density p?(x) = 1 {f(x) ≤ γ} p0(x)/pγ , where p0 is the density function of P0.
Indeed, since p0(x)/p?(x) = pγ if f(x) ≤ γ, the estimate p̂?N,γ := 1N
∑N
i=1
p0(Xi)
p?(Xi)
1 {f(Xi) ≤ γ}
is exact. However, sampling from this distribution requires knowledge of pγ , the quantity un-
der estimation. Instead, we consider a family of parameterized importance sampling distributions
Pθ for θ ∈ Θ, and use a model-based optimization method that iteratively modifies Pθ to better
approximation P ?.
In particular, we use the cross-entropy method [13], which iteratively approximates θ? ∈
argminθ∈ΘDkl (P
?||Pθ), the projection of P ? onto the class of parameterized distributions P =
{Pθ}θ∈Θ. We use natural exponential families as our model class P of importance samplers.
Since adverse events {f(X) ≤ γ} are rare, the cross-entropy method maintains a surrogate distribu-
tion qk(x) ∝ 1 {f(x) ≤ γk} p0(x) where γk ≥ γ is a (potentially random) sequence of alternative
thresholds γ. Using this multi-level approach, at each iteration we use samples from our current
iterate Pθ to update θ as an approximate projection of Qk onto P . Such a procedure is guided towards
distributions Pθ that upweights regions of X with low values of f(x) (unsafe regions). To choose the
level γk at each iteration k, we use an empirical estimate of the ρ-quantile of f(X) where X ∼ Pθk ,
where ρ ∈ (0, 1) (see [7] for other variants). Further details are provided in Appendix B.
The cross-entropy method (Algorithm 1 in Appendix B) is a model-based heuristic for approximating
the optimal importance sampler, θ? ∈ argminθ∈ΘDkl (P ?||Pθ). Empirically, we find that with
careful choice of hyperparameters, the cross-entropy method learns importance samplers that samples
risky scenarios much more frequently. We observe significant improvements over the naive Monte
Carlo method in our experiments, but we observe that the importance sampler focuses on a particular
“risk mode” of over-eating.
4 Results and Discussion
We investigate hypoglycemic events as failure modes for AP systems. Recall that APs are underactu-
ated systems which currently have the ability to lower, but not raise, blood glucose levels. As such,
we choose to simulate an evening meal followed by an overnight fast to capture the one of the most
dangerous time periods for a T1D patient, a period when they are incapacitated and cannot react to
hypoglycemia [8]. There are three classes of patients: children (under age 13), adolescents (between
ages 13 and 19), and adults (above age 19). We show in the sequel, the frequency of hypoglycemic
events subsequently varies considerably between children and both adolescents and adults.
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Figure 1: Number of hypoglycemic events f(X) ≤ γ out of 100K samples. Cross-entropy method
(orange) learns to sample 2-10 times more adverse events than naive Monte Carlo (blue).
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Figure 2: Standard deviation of empirical estimators for pγ = P0(f(X) ≤ γ) based on 100K
samples. By virtue of sampling more adverse-events, the importance sampling estimator based on the
cross-entropy method (orange) achieves 2-4 times variance reduction over naive Monte Carlo (blue).
We let the random variableX ∈ R63 be composed ofXup concatenated withXfc, such that a specific
realization of X defines a synthetic patient (Xup) as well as their evening meal carbohydrate intake
and overnight fasting time (Xfc). We define the risk f(X) as the minimum blood glucose level for a
patient during their simulated overnight fast. We choose a subset of one child, one adolescent, and
one adult form our population of 30 patients. For each patient, we compute both a naive Monte Carlo
estimate and an estimate utilizing the framework described in Section 3.
Since the feature vector X ∼ P0 is a logit-normal distribution, we posit the space of logit-normal
distributions as the model space searched over by the cross-entropy method. Concretely, we consider
logit-normal distributions with the same covariance structure. Formally, this is equivalent to taking a
logistic transform of X and searching over multivariate Gaussian distributions Pθ with covariance Σ̂
estimated in Section 2. Specifically, we consider the search space Θr = {θ : ‖θ − µ̂‖2 ≤ r} where µ̂
is the mean vector estimated in Section 2, and we choose r to maximize acceleration while retaining
numerical stability of the likelihood ratios.
We use ρ = 0.01, αk = .8 and Nk = 1000 samples per iteration of the cross-entropy method. We
observe that ρ is a crucial hyperparameter for achieving acceleration; we chose ρ = 0.01 based on
the number of adverse events sampled for the adult patient, and used it throughout all age groups. We
note that in order to avoid overfitting to the Nk samples drawn at each cross-entropy iteration, one
has to increase Nk appropriately as ρ approaches 0. Another crucial design choice that determine the
performance of the cross-entropy method is r, size of the search space. Based on a small preliminary
experiment, we fix them at {.1, .1, .5} for child, adolescent, and adult patients.
To evaluate the performance of our learned importance sampling distribution Pθ̂, we draw n =
100, 000 samples Xi
iid∼ Pθ̂ to simulate the minimum glucose level. In Figure 1, we find that the
cross-entropy method learns to sample hypoglycemic events 2-10 times more frequently compared to
the naive Monte Carlo method. We see in Figure 2 that our ability to sample more adverse events
leads to estimators with smaller variance. Since both naive Monte Carlo and importance sampling
estimators are unbiased, the observed variance reduction implies that the cross-entropy method can
significantly accelerate evaluation of adverse events. The relative variance reduction is especially
pronounced for the patient in the child group, whose probability of the adverse event is rarest out of
the three patients.
4
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A Generative Models
A.1 Eating and Overnight Fasting Behavior
We fit a distribution to the data in the following manner. Denoting Yfc ∈ R2 as the random variable
denoting overnight fasting time and the carbohydrate intake of the last meal prior to fasting, we
denote random variable Xfc with parameters afc, bfc, ufc, and Σfc as follows:
Xfc ∼ N (µfc,Σfc) (1a)
Yfc = (bfc − afc) × σ (Xfc) + afc (1b)
σ(t) =
1
1 + exp(−t) (1c)
where N (·, ·) is a multivariate normal distribution, and the operators σ(·), ×, and + operate element-
wise on vectors. The four parameters are fit from the empirical data distribution
{
Xifc
}n
i=1
with its
corresponding distribution Pe that places weight 1/n on each datapoint.
aˆfc = min
i
Y ifc (2a)
bˆfc = max
i
Y ifc (2b)
µˆfc = EPeσ−1
(
Yfc − aˆfc
bˆfc − aˆfc
)
(2c)
Σˆfc = CovPe
(
σ−1
(
Yfc − aˆfc
bˆfc − aˆfc
)
, σ−1
(
Yfc − aˆfc
bˆfc − aˆfc
))
, (2d)
σ−1(t) = log
(
t
1− t
)
, (2e)
where σ−1(·), min(·) and max(·) operate elementwise on vectors.
A.2 Physiological Parameters
We attempted to build a generative model of the 61 parameters Yup ∈ R61 required by the simulator
by fitting a logit-normal distribution to each of the three subpopulations of parameters in a manner
similar to that in Equation (2). Namely, we fit aˆup, bˆup, and µˆup using the same approach as in
Equations (2a), (2b), and (2c). Due to the high dimensionality of the data and the low sample size,
we replace Equation (2d) with the graphical lasso algorithm [6]. This method estimates the inverse
covariance matrix with the following convex optimization problem [6]:
Σˆ−1up = argmin
T0
tr(ST )− log detT + λ∑
j 6=k
|Tjk|
 ,
S = CovPe
(
σ−1
(
Yfc − aˆfc
bˆfc − aˆfc
)
, σ−1
(
Yfc − aˆfc
bˆfc − aˆfc
))
,
However, roughly 40% of 1,000,000 synthetic patients drawn from this model spontaneously become
dangerously hypoglycemic in short periods of time without taking insulin or eating any meals,
implying that the distribution is unrealistic (at least for use with the simulator). Attempts at refining
the sampling scheme using convex-hulls around the 60% of realistic synthetic patients were not
successful due to the high dimensionality of the space. Because the interdependencies between the
61 parameters are evidently paramount to ensuring realistic synthesis of patients, we move away
from attempting to build accurate subpopulation distributions given only 10 sample patients for each
subpopulation.
As noted in the main text, we design logit-normal distributions around each patient’s parameters by
first setting the compact interval range as 1/10 the interval range for the entire subpopulation centered
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Algorithm 1 Cross-Entropy Method
1: Input: Quantile ρ ∈ (0, 1), Stepsizes {αk}k∈N, Sample sizes {Nk}k∈N, Number of iterations K
2: Initialize: θ0 ∈ Θ
3: for k = 0, 1, 2, . . . ,K − 1 do
4: Sample Xk,1, . . . , Xk,Nk
iid∼ Pθk
5: Set γk as the minimum of γ and the ρ-quantile of f(Xk,1), . . . , f(Xk,Nk)
6: θk+1 = argmaxθ∈Θ
{
αkθ
>Dk+1 + (1− αk)θ>∇A(θk)−A(θ)
}
7: end for
at the patient’s parameters. Namely, for patient i, we have:
aˆiup = Y
i
up −
bˆup − aˆup
20
(3a)
bˆiup = Y
i
up +
bˆup − aˆup
20
, (3b)
where the operator − is elementwise over vectors.2 Then, we choose the mean and covariance as
follows:
µˆiup = σ
−1
(
Y iup − aˆiup
bˆiup − aˆiup
)
(3c)
Σˆiup = 0.25I, (3d)
This covariance structure encodes the fact that we have no knowledge of the covariance of the minute
variations in the 61 parameters for an individual patient; it approximates a normal distribution with
roughly 99% of the probability mass in the interval [aˆiup + 0.2(bˆ
i
up − aˆiup), bˆiup − 0.2(bˆiup − aˆiup)].
B The Cross-entropy method
Concretely, consider the following updates to the parameter vector θk at iteration k: compute
projections of a mixture of Qk and Pθk onto P
θk+1 = argmin
θ∈Θ
Dkl (αkQk + (1− αk)Pθk ||Pθ)
= argmax
θ∈Θ
{αkEQk [log pθ(X)] + (1− αk)Eθk [log pθ(X)]}
= argmax
θ∈Θ
{
αkθ
>EQk [Γ(X)] + (1− αk)θ>∇A(θk)−A(θ)
}
. (4)
However, the EQk [Γ(X)] term is unknown so we use an empirical approximation. For
Xk,1, . . . , Xk,Nk
iid∼ Pθk , letting γk be the ρ-quantile of f(Xk,1), . . . , f(Xk,Nk) and
Dk+1 :=
1
Nk
Nk∑
i=1
qk(Xk,i)
pθk(Xk,i)
Γ(Xk,i)
=
1
Nk
Nk∑
i=1
p0(Xk,i)
pθk(Xk,i)
1 {f(Xk,i) ≤ γk}Γ(Xk,i), (5)
we use Dk+1 in place of EQk [Γ(X)] in the idealized update (4). Summarizing this procedure, we
obtain Algorithm 1; as our final importance sampler, we choose θk with the lowest ρ-quantile of
f(Xk,i).
2For some dimensions, aˆiup must be set as
(
Y iup − bˆup−aˆup20
)
+
since the parameter must be nonnegative.
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